Immunological cytokine correlates of protective immunity and pathogenesis in leprosy

Scandinavian Journal of Immunology

Volumn 51, Issue 4, 2000, Pages 419-428

  Lima, M C B S ^a,b   Pereira, G M B ^a,b   Rumjanek, F D ^c   Gomes, H M ^a   Duppre, N ^a   Sampaio, E P ^a   Alvim, I M P ^a   Nery, J A C ^a   Sarno, E N ^a   Pessolani, Maria Cristina Vidal ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; LEPROSY; MONONUCLEAR CELL; MYCOBACTERIUM LEPRAE; PATHOGENESIS; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; AGED; BCG VACCINE; CHILD; HUMANS; IMMUNITY; INTERFERON TYPE II; INTERLEUKIN-10; LEPROSY; LEPROSY, LEPROMATOUS; LEPROSY, TUBERCULOID; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MYCOBACTERIUM LEPRAE; SKIN TESTS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 0034003429     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2000.00703.x     Document Type: Article

References (46)

1. WHO. Leprosy elimination campaigns (LECs). Progress during 1997-1998. Weekly Epidemiol Rec 1998;73:177-84.
2. Haanen JB, de Waal Malefyt R, Res PC, et al. Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med 1991;174:583-92.
3. Britton WJ. Immunology of leprosy. Trans R Soc Trop Med Hyg 1993;87:508-14.
4. Bjune G, Barnetson S, Ridley DS, Kronvall G. Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions. Clin Exp Immunol 1976;25:85-94.
5. Misra N, Murtaza A, Walker B, et al. Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae. Immunology 1995;86:97-103.
6. Mutis T, Kraakman EM, Cornelisse YE, et al. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. J Immunol 1993;150:4641-51.
7. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991;254:277-9.
8. Godal T, Negassi K. Subclinical infection in leprosy. Br Med J 1973;3:557-9.
9. Garcia I, Miyazaki Y, Marchal G, Lesslauer W, Vassalli P. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997;27:3182-90.
10. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-40.
11. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993;178:2243-7.
12. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
13. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-9.
14. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-67.
15. Launois P, Niang MN, De Bruyn J, et al. The major secreted antigen complex (Ag 85) from Mycobacterium bovis bacille Calmette-Guerin is associated with protective T cells in leprosy: a follow-up study of 45 household contacts. J Infect Dis 1993;167:1160-7.
16. Sampaio EP, Moreira AL, Kaplan G, et al. Mycobacterium leprae-induced interferon-gamma production by household contacts of leprosy patients: association with the development of active disease. J Infect Dis 1991;164:990-3.
17. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996;348:17-24.
18. Convit J, Sampson C, Zuniga M, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet 1992;339:446-50.
19. Matos HJ, Duppre N, Alvim MFS, Vieira LMM, Sarno EN, Struchiner CJ. Leprosy epidemiology in a cohort of household contacts in Rio de Janeiro (1987-1991). Cas Saúde Pública. Rio Janeiro 1999;15:533-42.
20. Cho S, Fujiwara T, Hunter SW, Rea TH, Gelber RH, Brennan PJ. Use of an artificial antigen containing the 3,6-di-O-methyl-beta-D-glupyranosyl epitope for the serodiagnosis of leprosy. J Infect Dis 1984;150:311-22.
21. Hunter SW, Rivoire B, Mehra V, Bloom BR, Brennan PJ. The major native proteins of the leprosy bacillus. J Biol Chem 1990;265:14065-8.
22. Pessolani MC, Peralta JM, Rumjanek FD, et al. Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from Mycobacterium bovis BCG. J Clin Microbiol 1991;29:2285-90.
23. Baumgart KW, Britton WJ, Mullins RJ, Basten A, Barnetson RS. Subclinical infection with Mycobacterium leprae - a problem for leprosy control strategies. Trans R Soc Trop Med Hyg 1993;87:412-15.
24. Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor necrosis factor production in patients with leprosy. Infect Immun 1992;60:1441-6.
25. Flad HD, Gercken J, Hubner L, Schluter C, Pryjma J, Ernst M. Cytokines in mycobacterial infections: in vitro and ex vivo studies. Arch Immunol Ther Exp 1995;43:153-8.
26. Orme IM, Roberts AD, Griffin JP, Abrams JS. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol 1993;151:518-25.
27. Sieling PA, Abrams JS, Yamamura M, et al. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J Immunol 1993;150:5501-10.
28. Katoch K, Ramu G, Ramanathan U, et al. Results of a modified WHO regimen in highly bacilliferous BL/LL patients. Int J Lepr Mycobact Dis 1989;57:451-7.
29. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
30. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998;8:275-83.
31. Kemp K, Hviid L, Kharazmi A, Kemp M. Interferon-gamma production by human T cells and natural killer cells in vitro in response to antigens from the two intracellular pathogens Mycobacterium tuberculosis and Leishmania major. Scand J Immunol 1997;46:495-9.
32. Smith D, Hansch H, Bancroft G. Ehlers S. T-cell-independent granuloma formation in response to Mycobacterium avium: role of tumour necrosis factor-alpha and interferon-gamma. Immunology 1997;92:413-21.
33. Kawamura I, Tsukada H, Yoshikawa H, Fujita M, Nomoto K, Mitsuyama M. IFN-gamma-producing ability as a possible marker for the protective T cells against Mycobacterium bovis BCG in mice. J Immunol 1992;148:2887-93.
34. Ravn P, Boesen H, Pedersen BK, Andersen P. Human T cell responses induced by vaccination with Mycobaterium bovis bacillus Calmette-Guerin. J Immmunol 1997;158:1949-55.
35. Andersen P. Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Scand J Immunol 1997;45:115-31.
36. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2:893-8.
37. Stewart-Tull DES. Immunologically important constituents of mycobacteria: adjuvants. In: Ratledge C, Stanford J, eds. The Biology of the Mycobacteria, Volume, Vol. 2. London: Academic Press, 1983;3-84.
38. Yang J, Mitsuyama M. An essential role for endogenous interferon-gamma in the generation of protective T cells against Mycobacterium bovis BCG in mice. Immunology 1997;91:529-35.
39. Flesch IE, Hess JH, Huang S, et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995;181:1615-21.
40. Misra N, Selvakumar M, Singh S, et al. Monocyte derived IL-10 and PGE2 are associated with the absence of Th1 cells and in vitro T cell supression in lepromatous leprosy. Immunol Lett 1995;48:123-8.
41. Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-84.
42. Cheng SH, Walker KB, Lowrie DB, et al. Monocyte antimycobacterial activity before and after Mycobacterium bovis BCG vaccination in Chingleput, India and London, United Kingdom. Infect Immun 1993;61:4501-3.
43. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45.
44. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Res Respir Dis 1966;94:553-68.
45. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor deficient patients. Science 1998;280:1435-8.
46. Hill AV. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998;16:593-617.